Multiple System Atrophy clinical trials at University of California Health
9 in progress, 5 open to eligible people
GDNF Gene Therapy for Multiple System Atrophy
open to eligible people ages 35-75
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
at UC Irvine
Study of ATH434 in Participants With Multiple System Atrophy
open to eligible people ages 30-75
This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy
at UCSD
Trial of Parkinson's And Zoledronic Acid
open to eligible people ages 60 years and up
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.
at UC Davis UC Irvine UCLA UCSF
Automated Imaging Differentiation of Parkinsonism
open to eligible people ages 40-80
The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.
at UCSD UCSF
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
open to eligible people ages 35-75
The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.
at UC Irvine
A Study of Lu AF82422 in Participants With Multiple System Atrophy
Sorry, in progress, not accepting new patients
To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.
at UCSD UCSF
A Study of TAK-341 in Treatment of Multiple System Atrophy
Sorry, not currently recruiting here
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.
at UCLA
North American Prodromal Synucleinopathy Consortium
Sorry, accepting new patients by invitation only
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
at UCLA
North American Prodromal Synucleinopathy Consortium Stage 2
Sorry, not currently recruiting here
This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
at UCLA
Our lead scientists for Multiple System Atrophy research studies include Jill Ostrem, MD Ece Bayram,, MD, PhD Nicolas Phielipp, MD Susan Perlman Caroline Tanner, MD Alon Avidan, MD, MPH.
Last updated: